Corrigendum to 'Long-term outcomes to neoadjuvant pembrolizumab based on pathological response for patients with resectable stage III/IV cutaneous melanoma': [Annals of Oncology 34 (2023) 806-812].
Ann Oncol
; 35(8): 756, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-38614876
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2024
Document type:
Article
Country of publication:
United kingdom